Connect with us

Hi, what are you looking for?


CVS, Walgreens to pay combined $10.7 billion for alleged opioid prescription lapses

CVS and Walgreens have agreed to pay a combined $10.7 billion to settle allegations they failed to adequately oversee opioid painkiller prescriptions, thus contributing to America’s opioid addiction crisis.

The funds will be distributed to states, local governments and federally recognized tribes and will go toward opioid crisis abatement and remediation programs. CVS will pay $4.9 billion to states and political subdivisions and approximately $130 million to tribes. Walgreens will pay $4.95 billion, plus more than $750 million in fees for attorneys and costs. The payments will be made over time.  

The pharmacy chains have also agreed to implement robust controlled substance compliance programs that will require additional layers of opioid prescription reviews and institute new mandatory training programs.

Between 2011 and 2020, the overdose death rate from all opioids tripled, from 7.3 deaths per 100,000 people to 21.4 deaths per 100,000 people, according to the nonprofit State Health Access Data Assistance Center. Even as declines from prescriptions like oxycontin have leveled off, deaths from heroin, which is illegal, and fentanyl, a commonly prescribed painkiller, have surged, the group said.

‘When people can’t simply stop their consumption, as in the case of addiction, they often turn to substitutes,’ wrote Colin Planalp, a research fellow at the center. ‘With opioids, that unfortunately left many people to seek out substances such as heroin on the illicit market, where the purity and potency is unreliable, making them even riskier than prescription opioids. And once drug traffickers embraced the potent opioid fentanyl, it pervaded the illegal drug trade and became entangled with non-opioid substances, such as cocaine and methamphetamine.’

Illinois Attorney General Kwame Raoul led the settlement effort.

“The opioid epidemic has tragically affected too many Illinois families that have experienced addiction or even the death of a loved one,’ he said in a statement. ‘This $10.7 billion settlement with Walgreens and CVS builds upon the important progress we’ve already achieved with previous settlements, but more importantly, it holds both companies accountable.’

As part of the settlement, neither company admitted to wrongdoing.

“We are pleased to resolve these longstanding claims and putting them behind us is in the best interest of all parties, as well as our customers, colleagues and shareholders,” Thomas Moriarty, chief policy officer and general counsel, CVS Health, said in a release. “We are committed to working with states, municipalities and tribes, and will continue our own important initiatives to help reduce the illegitimate use of prescription opioids.”

“As one of the largest pharmacy chains in the nation, we remain committed to being a part of the solution, and this settlement framework will allow us to keep our focus on the health and wellbeing of our customers and patients, while making positive contributions to address the opioid crisis,’ Walgreens said in a statement.

This post appeared first on NBC NEWS

    You May Also Like


    The 2023 NTT IndyCar season kicks off this weekend in Florida following an offseason of change in the paddock. Eight full-time IndyCar drivers —...


    Four division titles — AFC East, NFC East, AFC South and NFC South — will be decided in NFL Week 18. In all, 11...


    Kalen DeBoer says Nick Saban will retain ‘100% access’ to Alabama football program, with DeBoer’s blessingNick Saban wasn’t over Kalen DeBoer’s shoulder at introductory...


    The Kansas City Chiefs and Miami Dolphins have weathered various storms throughout the regular season, from injuries to inconsistent play, but on Saturday, both...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 | All Rights Reserved